Table 5.
Summary of total cholesterol and low-density lipoprotein cholesterol (LDL-C) outcomes for the combined digital medicine offering (DMO) group only.a
| Outcome | Usual care | DMO (combined) | |||
| Value | Value | Difference,b
(95% CI) |
Adjusted difference,b
(95% CI) |
||
| Total cholesterol (mg/dL)c | |||||
| Baseline, mean (SE) | 174.4 (13.1) | 177.4 (9.5) | |||
| Week 4, mean change (SE) | –9.2 (7.1) | –34.8 (7.1) | –25.7 (9.7); (–44.6, –6.7) |
–23.0 (7.8); (–38.2, –7.8) |
|
| Week 12, mean change (SE) | –21.9 (10.2) | –29.5 (7.4) | –7.9 (11.3); (–30.1, 14.3) |
–8.1 (7.9); (–23, 7) |
|
| LDL-C (mg/dL)c | |||||
| Baseline, mean (SE) | 99.3 (6.7) | 103.9 (10.1) | |||
| Week 4, mean change (SE) | –3.7 (3.8) | –29.7 (9.4) | –25.6 (9.4); (–44.1, –7.1) |
–22.7 (6.1); (–34.6, –10.8) |
|
| Week 12, mean change (SE) | –9.5 (5.6) | –21.3 (10.0) | –11.0 (13); (–37.4, 15.4) |
–10.8 (6.3); (–23.1, 1.5) |
|
| Total cholesterol with baseline LDL ≥70 mg/dL (mg/dL)d | |||||
| Baseline, mean (SE) | 174.1 (11.6) | 185.1 (8.4) | |||
| Week 4, mean change (SE) | –7.0 (6.9) | –39.8 (7.9) | –32.9 (10.2); (–52.9, –12.9) |
–26.5 (9.1); (–44.4, –8.6) |
|
| Week 12, mean change (SE) | –18.9 (9.4) | –37.7 ± 7.5 | –18.8 ± 10.6; (–39.6, 2.0) |
–13.9 ± 8.8; (–31.2, 3.3) |
|
| LDL-C with baseline LDL ≥70 mg/dL (mg/dL)d | |||||
| Baseline, mean (SE) | 104.2 (7.0) | 114.0 (7.1) | |||
| Week 4, mean change (SE) | –4.0 (4.3) | –37.2 (7.9) | –33.2 (8.9); (–50.6, –15.8) |
–25.3 (7.0); (–39.1, –11.6) |
|
| Week 12, mean change (SE) | –10.9 (5.9) | –30.1 (8.0) | –19.2 (8.9); (–36.4, –2.0) |
–13.4 (7.1); (–27.4, 0.5) |
|
aDue to small sample sizes for DMO groups, results are summarized.
bDifference from usual care.
cIncludes participants on any statin therapy in usual care (n=23) and on digital atorvastatin in the DMO group (n=41).
dIncludes participants on statin therapy in usual care (n=20) and on digital atorvastatin in the DMO group (n=34).